Company Description
KALA BIO, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases.
The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery.
Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases.
The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023.
KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
| Country | United States |
| Founded | 2009 |
| IPO Date | Jul 20, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 43 |
| CEO | Mark T. Iwicki |
Contact Details
Address: 1167 Massachusetts Avenue Arlington, Massachusetts 02476 United States | |
| Phone | 781-996-5252 |
| Website | kalarx.com |
Stock Details
| Ticker Symbol | KALA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001479419 |
| CUSIP Number | 483119103 |
| ISIN Number | US4831192020 |
| Employer ID | 27-0604595 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Mark T. Iwicki | Chairman and Chief Executive Officer |
| Todd Bazemore | President and Chief Operating Officer |
| Dr. Kim Brazzell Ph.D. | Head of Research & Development and Chief Medical Officer |
| Dr. Justin Hanes Ph.D. | Founder and Chair of the Scientific Advisory Board |
| Mary Reumuth CPA | Chief Financial Officer and Treasurer |
| Jill S. Steier | Executive Director of Investor Relations and Corporate Communications |
| Eric L. Trachtenberg | Chief Legal Officer, Chief Compliance Officer and Corporate Secretary |
| Vincent Kosewski | Senior Vice President of Manufacturing and Supply Chain Management |
| Darius Kharabi J.D., M.B.A. | Chief Business Officer |
| Dr. Francis S. Mah M.D. | Chief Medical Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 19, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 29, 2024 | 424B5 | Filing |
| Mar 29, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 29, 2024 | 10-K | Annual Report |
| Mar 29, 2024 | 8-K | Current Report |
| Mar 26, 2024 | 8-K | Current Report |
| Mar 4, 2024 | 8-K | Current Report |
| Feb 16, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |